Eli Lilly Receives FDA Approval for Alzheimer's Disease Drug Donanemab

The US FDA has approved donanemab from Eli Lilly (NYSE: LLY) as a treatment for early-stage Alzheimer's disease.

This remedy, which is administered as an infusion once a month, is sold under the name “Kisunra.”

According to Lilly, treatment costs $12,522 for 6 months and $32,000 for 1 year. The 12-month cost includes 13 infusions, and the 6-month cost assumes 6 doses.

The US FDA advisory committee in June unanimously approved that this remedy is effective.

Kisunra competes with Biogen (BIIB) and lecanemab (lecanemab) of Eisai (OTCPK: ESALF) (OTCPK: ESAIY).

Leqembi is administered every 2 weeks, and the 1-year list price is $26,500. However, the FDA is to decide whether to approve the monthly dosage version in January 2025.